Antares Pharma Inc. (ATRS) Downgraded by Zacks Investment Research to “Hold”
Antares Pharma Inc. (NASDAQ:ATRS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.
According to Zacks, “Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes its needle-free injector systems for the delivery of insulin and growth hormone in over 20 countries and an estradiol transdermal patch for hormone replacement therapy. “
Separately, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $2.00 price target (down previously from $3.00) on shares of Antares Pharma in a report on Saturday, August 13th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/antares-pharma-inc-atrs-downgraded-by-zacks-investment-research-to-hold.html
Antares Pharma (NASDAQ:ATRS) traded down 1.11% during mid-day trading on Tuesday, hitting $1.78. The company’s stock had a trading volume of 579,111 shares. The firm’s 50-day moving average is $1.49 and its 200-day moving average is $1.12. The company’s market cap is $276.00 million. Antares Pharma has a 12-month low of $0.67 and a 12-month high of $1.85.
Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.04). The firm earned $12.20 million during the quarter, compared to analyst estimates of $11 million. Antares Pharma had a negative return on equity of 41.06% and a negative net margin of 54.98%. During the same quarter in the previous year, the business earned ($0.01) earnings per share. Analysts predict that Antares Pharma will post ($0.15) EPS for the current fiscal year.
A number of hedge funds have recently bought and sold shares of ATRS. Geode Capital Management LLC raised its stake in Antares Pharma by 0.7% in the first quarter. Geode Capital Management LLC now owns 922,527 shares of the specialty pharmaceutical company’s stock worth $802,000 after buying an additional 5,999 shares in the last quarter. Oppenheimer & Co. Inc. raised its stake in Antares Pharma by 19.1% in the second quarter. Oppenheimer & Co. Inc. now owns 112,300 shares of the specialty pharmaceutical company’s stock worth $118,000 after buying an additional 18,000 shares in the last quarter. Janus Capital Management LLC bought a new stake in Antares Pharma during the second quarter worth $102,000. William Harris Investors Inc. raised its stake in Antares Pharma by 7.0% in the first quarter. William Harris Investors Inc. now owns 1,736,256 shares of the specialty pharmaceutical company’s stock worth $1,511,000 after buying an additional 113,307 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in Antares Pharma during the second quarter worth $133,000. Institutional investors own 36.34% of the company’s stock.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.